Please assess the completion status of the following clinical trial:

Trial Title: Antimicrobial Therapy for Ulcerative Colitis (UC)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Established diagnosis of UC, disease confined to the large intestine, involving the rectosigmoid for at least 3 months.~2. Weight \>30 kg~3. Mild to Moderate active disease, SCCAI of ≥5 and ≤ 10, 10 ≤ PUCAI ≤4.~4. Refractory to mesalamine 6 weeks, or steroids \> 14 days, or immunomodulator 12 weeks or biologics at least 12 weeks therapy.~Exclusion Criteria:~1. Start of a new biologic in the previous 12 weeks.~2. Proctitis~3. Evidence for Clostridium difficile infection.~4. Any proven current infection such as CMV, positive stool culture or parasite.~5. Current Extra intestinal manifestation of UC such as active arthritis or PSC.~6. Immune deficiency (other than drug induced).~7. Current use of a calcineurin inhibitor~8. Pregnancy.~9. Suspected toxic megacolon, guarding on palpation, or signs of peritoneal inflammation~10. Patients with other IBD unrelated disease such as autoimmune disorders, renal failure, fever or current infection (UTI, strep throat, pneumonia, etc), prior or current neoplasia~11. Fever \>38~12. Participation in another clinical interventional trial~13. An active malignant disease or a prior malignancy during the previous 5 years (excluding skin BCC).~14. Anticipation for antibiotic use within the study period (such as for elective surgery or dental treatment).~15. Acute severe UC in the past 3 months.~16. Presence of a pouch or pouchitis.

- Gender: ALL
- Minimum Age: 13 Years
- Maximum Age: 60 Years
- Healthy Volunteers: f

Study Arms:
- Group 1 -Amoxycillin Doxycyclin and metronidazole (Type: ACTIVE_COMPARATOR): triple therapy with amoxicillin, metronidazole and tetracycline twice daily, for 2 weeks.
- Group 2 -Amoxycillin and Doxycyclin (Type: EXPERIMENTAL): double therapy with Amoxycillin and Doxycyclin twice daily, for 2 weeks.

Based on this trial design, predict the completion outcome and termination type (if applicable).